Keyphrases
Phase II Trial
100%
Myasthenia Gravis
100%
Rituximab
100%
Prednisone
66%
Myasthenia Gravis Foundation of America
50%
Rituximab Therapy
50%
Steroid-sparing
50%
Informed Consent
50%
Placebo Groups
33%
Dose Reduction
33%
2-cycles
33%
AChR Antibodies
33%
Stable Dose
33%
Myasthenia
33%
Acetylcholine Receptor (AChR)
33%
Chest CT
33%
Treatment Group
33%
Delayed Benefits
16%
Thymoma
16%
Antibody Titer
16%
Medical Laboratory
16%
Birth Method
16%
Steroid Reduction
16%
Reproductive Potential
16%
Pregnancy Test
16%
Mg Composites
16%
Tumor Virus Infections
16%
Pyridostigmine
16%
Neurologic
16%
Classification System
16%
Population Sample
16%
Primary Outcome Measure
16%
Vehicle Control
16%
Immunosuppression
16%
Clinical Outcome Measures
16%
Childbearing Women
16%
Randomized Placebo-controlled Trial
16%
Rochester
16%
Clinical Endpoints
16%
Effective Treatment
16%
Inclusion Criteria
16%
Clinical Improvement
16%
Safe Treatment
16%
Scientific Advisory Board
16%
Birth Control
16%
Exclusion Criteria
16%
Interstitial Lung Disease
16%
Treatment Completion
16%
Composite Score
16%
CT-MRI
16%
Specific Intent
16%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Phase II Trials
100%
Myasthenia gravis
100%
Prednisone
44%
Placebo
33%
Myasthenia
22%
Treatment Group
22%
Controlled Clinical Trial
11%
Physical Disease by Body Function
11%
Infection
11%
Retrospective Study
11%
Interstitial Lung Disease
11%
Pyridostigmine
11%
Neoplasm
11%
Thymus Cancer
11%
Diseases
11%